Abstract:Introduction Implantation of cardioverter-defibrillator and/or resynchronization (ICD and CRT-D) devices is aimed to prevent sudden cardiac death, fatal complication of heart failure with reduced ejection fraction (HFrEF). Guidelines propose a period of 3 months receiving maximally titrated guideline-directed medical therapy (GDMT) prior to implantation. Ventricular tachycardia (VT) burden in HFrEF has been related to worse outcomes. The effect of GDMT up-titration on VT incidence after device implantation has not yet been fully clarified. Purpose The main goal of this study is to examine the effects of GDMT evidence-based target doses on VT and appropriate device therapy (ADT) incidence in patients with HFrEF implanted with ICD or CRT-D. Methods This registry-based study included patients with HFrEF who were implanted with ICD or CRT-D from January 2021 to November 2023, with at least one follow-up. Titration of GDMT and incidence of VT/ADT were evaluated. We compared VT/ADT incidence in target dose group to incomplete titration group of each drug class. We also compared GDMT titration and VT/ADT incidence in CRT-D to ICD group. The Fisher exact test was used to evaluate the differences between groups. Results Data on 132 patients were collected (mean age 63±26 years, 16% female). Median follow-up time from device implantation was 201 (30-748) days. Target doses were reached for 24.4% beta blockers (BB), 37.8% angiotensin receptor neprilysin inhibitors (ARNI), 73.5% mineralocorticoid receptor antagonists (MRA), 89.5% sodium-glucose contransporter-2 inhibitors (SGLT2I), and 18.8% of complete GDMT. Total VT and ADT incidence was 32.6% and 12.9%, respectively. In target doses vs. incomplete doses groups, VT incidence was 34.4% vs. 32.0% (p=.83) for BB, 28.0% vs. 35.4% (p=.45) for ARNI, 32.0% vs. 34.3% (p=.84) for MRA, 30.1% vs. 50.0% (p=.23) for SGLT2I and 33.3% vs. 32.4% (p=1) for complete GDMT. ADT incidence was 18.8% vs. 11.0% (p=.36) for BB, 12.0% vs. 13.4% (p=1) for ARNI, 12.4% vs. 14.3% (p=.77) for MRA, 11.0% vs. 21.4% (p=.39) for SGLT2i, and 16.7% vs. 12.0% (p=.51) for complete GDMT. In CRT-D vs. ICD group, 31.5% vs. 19,2% (p=.15) BB, 44.4% vs. 33.3% (p=.21) ARNI, 79.6% vs. 69.2% (p=.16) MRA, 98.1% vs. 83.3% (p<0.05) SGLT2I; and 20.4% vs. 16.7% (p=.65) of complete GDMT were maximally titrated. VT incidence was significantly lower in CRT-D group (18.5% vs. 42.3%, p<0.05). ADT was also lower, but without statistical significance (9.3% vs. 15.4%, p=.43). Conclusions Up-titration of any individual drug or complete GDMT to the evidence-based target dose did not directly correlate with a decrease in VT or ADT incidence. Cardiac resynchronization therapy provides more room for target GDMT doses, particularly of BB. We notice only a modest trend in up-titration of GDMT in patients with CRT-D, who had significantly lower incidence of VT.

Comparison Of Time To Guideline Directed Medical Therapy In Ischemic And Non Ischemic Cardiomyopathies

Different Clinical Features, Biochemical Profiles, Echocardiographic and Elctrocardiographic Findings in Older and Younger Patients with Idiopathic Dilated Cardiomyopathy

Impact of guideline directed medical therapy on myocardial function in adults with congenital heart disease

The prognosis evaluation of guideline-directed medical therapy for type 2 acute myocardial infarction patients with acute respiratory failure

Ventricular tachycardia burden in heart failure with reduced ejection fraction - can we rely on optimized medical therapy

The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry

Abstract 14740: Identifying Predictors of Timing to Guideline-Directed Medical Therapy for Medical Beneficiaries With Heart Failure

Comparing outcomes in cardiogenic shock patients with ischemic versus nonischemic cardiomyopathy: A nationwide retrospective observational study

Deceleration Time in Ischemic Cardiomyopathy

Guideline-directed medical therapy titration for heart failure with ischaemic aetiology and its effect on cardiac remodelling and cardiovascular mortality-from a real world perspective

Protocol-driven approach to guideline-directed medical therapy optimization for heart failure: A real-world application to recovery

Cardiac Resynchronization Therapy with Defibrillator in Ischemic Versus Nonischemic Cardiomyopathy

Outcomes with guideline-directed medical therapy and cardiac implantable electronic device therapies for patients with heart failure with reduced ejection fraction

Guideline-Directed Medical Therapy for Elderly Patients With Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention ― Insights From a Retrospective Observational Study ―

Does Duration Of Gdmt Up-titration Affect The Percentage Of Hfimpef Attainment?

Guideline‐directed medical therapy implementation during hospitalization for cardiogenic shock

Relationships between 18-month kinetics and functional capacity and left ventricular remodeling and cardiac fibrosis in dilated cardiomyopathy

The Use Of Inotropic Vasodilators In Transthyretin Amyloid Patients Presenting With Cardiogenic Shock: Descriptive Case Series

Treatment strategy for heart failure patients with guideline-directed medical therapy intolerance: a real-world prospective study

Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial

Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial